MolecularMD Licenses Rights to Commercialize Technology Aimed at Endometrial Cancer | GenomeWeb

NEW YORK (GenomeWeb News) – MolecularMD said today it has secured the rights to commercialize IP surrounding fibroblast growth factor receptor 2 activating mutations for diagnostic, prognostic, and predictive purposes in human endometrial cancer.

Rights to the IP are jointly held by Washington University in St. Louis and the Translational Genomics Research Institute.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: phosphoproteomic patterns in prostate cancer, effect of gene expression on fitness in yeast, and more.

Scripps Research Institute investigators peer back at the RNA world.

Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.